ScienHub

People attending a scientific conference Test tubes in a lab tray People attending a conference

We enable the scientific community to achieve excellence

At ScienHub we offer comprehensive solutions for the implementation of clinical research and knowledge transfer. We accompany the scientific community in all phases of its specialized work, ensuring the quality and effectiveness of the results obtained.

Units

  • ScienHub
    Research Support

    Unit specialized in the management and development of clinical studies. We promote research by offering comprehensive support in the management and implementation of projects, ensuring their quality and offering maximum reliability of the results obtained.

  • ScienHub
    Education

    Unit dedicated to the dissemination and knowledge transfer in the medical and scientific field. We promote the professional growth of the scientific community by creating spaces to share and expand knowledge.

ScienHub in 2023

  • ScienHub

    Support to multiple therapeutic areas

    • Cardiology
    • Covid-19 and Long-Covid
    • Dermatology
    • Gastroenterology
    • Hematology
    • Immunology
    • Nephrology
    • Oncology
    • Rheumatology
    • Urology
    • HIV
  • Education

    +50
    activities

    We have offered a wide variety of courses, conferences, congresses and webinars in all formats (face-to-face, hybrid and online).

  • Education

    +3.180
    attendees

    The professionals who attended our training activities in 2023 were primarily specialist doctors (27.1%), followed by primary care physicians (15.1%), and students (13.3%).

  • CRO

    60
    studies managed

    From the Contract Research Organization (CRO), we have managed 23 clinical trials, 20 research projects, 10 investigations involving medical devices, 4 cohorts, and 3 observational studies with pharmaceuticals.

  • Test tubes in a tray
  • CTU

    59
    studies implemented

    From the Clinical Trials Unit (CTU), we have implemented 59 clinical studies: 4 of them were Phase I and II, and the rest were Phase III and IX trials, as well as cohorts.

  • ScienHub in 2023

  • ScienHub

    Support to multiple therapeutic areas

    • Cardiology
    • Covid-19 and Long-Covid
    • Dermatology
    • Gastroenterology
    • Hematology
    • Immunology
    • Nephrology
    • Oncology
    • Rheumatology
    • Urology
    • HIV
  • Education

    +50
    activities

    We have offered a wide variety of courses, conferences, congresses and webinars in all formats (face-to-face, hybrid and online).

  • Education

    +3.180
    attendees

    The professionals who attended our training activities in 2023 were primarily specialist doctors (27.1%), followed by primary care physicians (15.1%), and students (13.3%).

  • CRO

    60
    studies managed

    From the Contract Research Organization (CRO), we have managed 23 clinical trials, 20 research projects, 10 investigations involving medical devices, 4 cohorts, and 3 observational studies with pharmaceuticals.

  • Test tubes in a tray
  • CTU

    59
    studies implemented

    From the Clinical Trials Unit (CTU), we have implemented 59 clinical studies: 4 of them were Phase I and II, and the rest were Phase III and IX trials, as well as cohorts.

  • The success of the PAX study: An example of coordination and efficiency in clinical research

    The PAX study consisted of a phase 2 clinical trial, randomized and double-blind, which prevented both the participant and the researcher from knowing which treatment the participant was receiving. This study has been one of the examples in which, thanks to the teamwork between the different departments of ScienHub Research Support and the good coordination of all parties involved, we have been able to meet the established deadlines and ensure good traceability of all data obtained.

  • Lab technicians

    ScienHub Research Support contributes to the development of HIPRA's COVID-19 vaccine in the EU

    ScienHub Research Support has played a key role in the clinical trials for the development of HIPRA’s vaccine, the first recombinant protein bivalent COVID-19 vaccine authorized in the European Union, ScienHub CTU has coordinated the implementation of the trials at the Germans Trias i Pujol Hospital site and has been the CRO responsable for the monitoring of one of HIPRA’s trials (RBDCOV project).

  • Esquistosomiasi

    A community screening in Metropolitana Nord reveals a high prevalence of schistosomiasis

    In a community screening study conducted in Metropolitana Nord Area, ScienHub Research Support team has played a crucial role supporting the on-site implementation coordination, providing support with the study documentation and authorities submission, and conducting the study monitoring visits. The results indicate that schistosomiasis is a common and underdiagnosed infection in the exposed population, with serious complications affecting the quality of life of those infected.

    These findings underscores the need for healthcare policies to incorporate screening for this infection to enable early diagnosis and treatment, which could prevent complications and improve the quality of life for those affected.

  • Project HOLA: A new, more accessible and convenient treatment for people with HIV

    The HOLA study will be offering a new intramuscular injectable medication every two months (Cabotegravir LA + Rilpivirine LA), at Primary Care Centers (CAP) and Community Centers.

    The combination of Long-Acting Cabotegravir and Rilpivirine is the first injectable treatment for HIV to be approved in Spain, whose main importance resides in that it drastically reduces the frequency of administration in comparison with other available treatments, from daily to every two months. However, since its recent approval in Spain, this medication was only available in hospitals. ScienHub and the Fight Infections Foundation team are collaborating on the HOLA study, which gives now people living with HIV the opportunity to benefit from this treatment with more convenient and accessible options at the Checkpoint Community Center and Dr. Robert CAP. Furthermore, this is a multicenter study and involves healthcare centers located in Andalusia.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop